Larimar Therapeutics (LRMR) Expected to Post Quarterly Earnings on Thursday

Key Points

• Larimar Therapeutics is expected to report Q3 2026 results before market open on Thursday, November 5. Analysts anticipate a loss of $0.35 per share, with an earnings call scheduled for November 4 at 9:30 a.m. ET.
• The company reported a Q2 loss of $0.30 per share, beating the consensus estimate of a $0.38 loss. Analysts expect full-year and next-year losses of $1.37 and $1.32 per share, respectively.
• Larimar shares recently traded at $2.54, down substantially from their 12-month high of $6.42, while analysts maintain a consensus “Buy” rating and an average price target of $10.33.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.35) per share for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:30 AM ET.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.08. On average, analysts expect Larimar Therapeutics to post ($1.37) EPS for the current fiscal year and ($1.32) EPS for the next fiscal year.

Larimar Therapeutics Trading Up 6.3%

NASDAQ:LRMR opened at $2.54 on Thursday. Larimar Therapeutics has a 12 month low of $1.91 and a 12 month high of $6.42. The firm has a fifty day simple moving average of $3.28 and a 200-day simple moving average of $3.81. The company has a market capitalization of $263.86 million, a P/E ratio of -1.30 and a beta of 0.68.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on LRMR. Wedbush cut their target price on Larimar Therapeutics from $12.00 to $11.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Leerink Partners began coverage on Larimar Therapeutics in a research report on Monday, September 14th. They set an "outperform" rating and a $13.00 price target for the company. Finally, HC Wainwright began coverage on Larimar Therapeutics in a research note on Thursday, July 2nd. They set a "buy" rating and a $10.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Larimar Therapeutics presently has a consensus rating of "Buy" and an average target price of $10.33.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.